BACKGROUND: Although many studies suggest that, on average, depression-specific psychotherapy and antidepressant pharmacotherapy are efficacious, we know relatively little about which patients are more likely to respond to one versus the other. We sought to determine whether measures of spectrum psychopathology are useful in deciding which patients with unipolar depression should receive pharmacotherapy versus depression-specific psychotherapy. METHOD: A total of 318 adult out-patients with major depression were randomly assigned to escitalopram pharmacotherapy or interpersonal psychotherapy (IPT) at academic medical centers at Pittsburgh, Pennsylvania and Pisa, Italy. Our main focus was on predictors and moderators of time to remission on monotherapy at 12 weeks. RESULTS: Participants with higher scores on the need for medical reassurance factor of the Panic-Agoraphobic Spectrum Self-Report (PAS-SR) had more rapid remission with IPT and those with lower scores on the psychomotor activation factor of the Mood Spectrum Self-Report (MOODS-SR) experienced more rapid remission with selective serotonin reuptake inhibitor (SSRI) pharmacotherapy. Non-specific predictors of longer time to remission with monotherapy included several panic spectrum and mood spectrum factors and the Social Phobia Spectrum (SHY) total score. Higher baseline scores on the 17- and 25-item Hamilton Depression Rating Scales (HAMD-17 and HAMD-25) and the Work and Social Adjustment Scale (WSAS) also predicted a longer time to remission, whereas being married predicted a shorter time to remission. CONCLUSIONS: This exploratory study identified several non-specific predictors but few moderators of psychotherapy versus pharmacotherapy outcome. It offers useful indicators of the characteristics of patients that are generally difficult to treat, but only limited guidance as to who benefits from IPT versus SSRI pharmacotherapy.
RCT Entities:
BACKGROUND: Although many studies suggest that, on average, depression-specific psychotherapy and antidepressant pharmacotherapy are efficacious, we know relatively little about which patients are more likely to respond to one versus the other. We sought to determine whether measures of spectrum psychopathology are useful in deciding which patients with unipolar depression should receive pharmacotherapy versus depression-specific psychotherapy. METHOD: A total of 318 adult out-patients with major depression were randomly assigned to escitalopram pharmacotherapy or interpersonal psychotherapy (IPT) at academic medical centers at Pittsburgh, Pennsylvania and Pisa, Italy. Our main focus was on predictors and moderators of time to remission on monotherapy at 12 weeks. RESULTS:Participants with higher scores on the need for medical reassurance factor of the Panic-Agoraphobic Spectrum Self-Report (PAS-SR) had more rapid remission with IPT and those with lower scores on the psychomotor activation factor of the Mood Spectrum Self-Report (MOODS-SR) experienced more rapid remission with selective serotonin reuptake inhibitor (SSRI) pharmacotherapy. Non-specific predictors of longer time to remission with monotherapy included several panic spectrum and mood spectrum factors and the Social Phobia Spectrum (SHY) total score. Higher baseline scores on the 17- and 25-item Hamilton Depression Rating Scales (HAMD-17 and HAMD-25) and the Work and Social Adjustment Scale (WSAS) also predicted a longer time to remission, whereas being married predicted a shorter time to remission. CONCLUSIONS: This exploratory study identified several non-specific predictors but few moderators of psychotherapy versus pharmacotherapy outcome. It offers useful indicators of the characteristics of patients that are generally difficult to treat, but only limited guidance as to who benefits from IPT versus SSRI pharmacotherapy.
Authors: Sona Dimidjian; Steven D Hollon; Keith S Dobson; Karen B Schmaling; Robert J Kohlenberg; Michael E Addis; Robert Gallop; Joseph B McGlinchey; David K Markley; Jackie K Gollan; David C Atkins; David L Dunner; Neil S Jacobson Journal: J Consult Clin Psychol Date: 2006-08
Authors: A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Andrew A Nierenberg; Jonathan W Stewart; Diane Warden; George Niederehe; Michael E Thase; Philip W Lavori; Barry D Lebowitz; Patrick J McGrath; Jerrold F Rosenbaum; Harold A Sackeim; David J Kupfer; James Luther; Maurizio Fava Journal: Am J Psychiatry Date: 2006-11 Impact factor: 18.112
Authors: Jay C Fournier; Robert J DeRubeis; Richard C Shelton; Steven D Hollon; Jay D Amsterdam; Robert Gallop Journal: J Consult Clin Psychol Date: 2009-08
Authors: Giovanni B Cassano; Paola Rucci; Ellen Frank; Andrea Fagiolini; Liliana Dell'Osso; M Katherine Shear; David J Kupfer Journal: Am J Psychiatry Date: 2004-07 Impact factor: 18.112
Authors: P Rucci; M Miniati; A Oppo; M Mula; S Calugi; E Frank; M K Shear; M Mauri; S Pini; G B Cassano Journal: J Psychiatr Res Date: 2008-05-21 Impact factor: 4.791
Authors: S M Sotsky; D R Glass; M T Shea; P A Pilkonis; J F Collins; I Elkin; J T Watkins; S D Imber; W R Leber; J Moyer Journal: Am J Psychiatry Date: 1991-08 Impact factor: 18.112
Authors: Jay C Fournier; Robert J DeRubeis; Richard C Shelton; Robert Gallop; Jay D Amsterdam; Steven D Hollon Journal: Br J Psychiatry Date: 2008-02 Impact factor: 9.319
Authors: S Calugi; G B Cassano; A Litta; P Rucci; A Benvenuti; M Miniati; L Lattanzi; V Mantua; V Lombardi; A Fagiolini; E Frank Journal: J Affect Disord Date: 2010-09-15 Impact factor: 4.839
Authors: Jay C Fournier; Jill M Cyranowski; Paola Rucci; Giovanni B Cassano; Ellen Frank Journal: J Psychiatr Res Date: 2012-07-05 Impact factor: 4.791
Authors: Alette M Wessels; Yuyan Jin; Bruce G Pollock; Ellen Frank; Anne-Catherine Lange; Bernard Vrijens; Andrea Fagiolini; David J Kupfer; Paola Rucci; Gail Kepple; Joel Anderton; Joan Buttenfield; Robert R Bies Journal: Int Clin Psychopharmacol Date: 2012-11 Impact factor: 1.659